Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf(German Cancer Research Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ana Arance(Hospital Clínic de Barcelona), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Anna Maria Di Giacomo(University of Siena), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ralf Gutzmer(Medizinische Hochschule Hannover), Mario Mandalà(Ospedale Papa Giovanni XXIII), L. Thomas(Université Claude Bernard Lyon 1), Lev Demidov(Russian Cancer Research Center NN Blokhin), Claus Garbe(University of Tübingen), David Hogg(University Health Network), Gabriella Liszkay(National Institute of Oncology), Paola Queirolo(Ospedale Policlinico San Martino), Ernesto Wasserman, James Ford, Marine Weill(Novartis (Switzerland)), L. Andres Sirulnik, Valentine Jehl(Novartis (Switzerland)), Viviana Bozón(Array BioPharma (United States)), Georgina V. Long(The University of Sydney), Keith T. Flaherty(Massachusetts General Hospital)
Cited by 491Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis